Thursday, 15 November 2018

AstraZeneca's pivotal lung cancer trial fails main goal in late stage trial

AstraZeneca's combination of two immunotherapy drugs did not meet the main goal in a closely watched late stage study, the company said on Friday.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)